Why the study?
Postdischarge bleeding carries an adverse prognosis similar to an ischemic event, requiring tailored antithrombotic therapy based on individualized bleeding and ischemic risks.
Answers are grounded in this paper and cite their sources.
This review highlights the importance of balancing ischemic and bleeding risks to individualize antithrombotic therapy duration in patients undergoing PCI.
inhibitors are typically prescribed for a longer duration, prioritizing reduction in ischemic events over bleeding risk. Because postdischarge bleeding connotes an adverse prognosis similar to an ischemic event, postprocedure freedom from adverse outcomes can be best tailored by individualizing and recognizing the patient's bleeding and ischemic risks. This review of the contemporary and historical literature (PubMed, EMBASE, Cochrane Library) summarizes the available data, provides strategies to navigate these complex decisions, and helps individualize antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Ingraham et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: